Revenue
2023
Sagimet Biosciences Inc. (SGMT)
Price—Loading quote
Net income
2022
2023
2024
2025
Free cash flow
No reported data
Total cash / debt
CashTotal debt
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | — | — | $2.0M | — |
| Research & development | $39.1M | $38.4M | $19.8M | $24.9M |
| Operating expenses | $56.9M | $54.5M | $32.7M | $31.1M |
| Operating income | −$56.9M | −$54.5M | −$30.7M | −$31.1M |
| Net income | −$51.0M | −$45.6M | −$27.9M | −$30.5M |
| Basic EPSper diluted share | -$1.58 | -$1.45 | -$2.66 | -$165.20 |
| Diluted EPSper diluted share | -$1.58 | -$1.45 | -$2.66 | -$165.20 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Feb 10, 2026Form 4 | Happel DavidPresident & CEO | SellSeries A Common Stock | 12.1K | $5.36 | $64.9K | 677.6K |
| Feb 10, 2026Form 4 | Chauche ThierryChief Financial Officer | SellSeries A Common Stock | 1.3K | $5.36 | $7.0K | 15.7K |
| Feb 10, 2026Form 4 | Martins Eduardo BrunoChief Medical Officer | SellSeries A Common Stock | 3.6K | $5.36 | $19.5K | 103.3K |
| Feb 10, 2026Form 4 | Rozek ElizabethChief Legal & Admin. Officer | SellSeries A Common Stock | 2.6K | $5.36 | $14.1K | 191.0K |
| Nov 20, 2025Form 4 · 10b5-1 | Kemble GeorgeExecutive Chairman | SellSeries A Common Stock | 37.7K | $7.69 | $289.8K | 81.0K |